Malignant Neoplasm of Stomach Completed Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02726399Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric CancerTreatment
NCT01461057A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric CancerTreatment
NCT01748773A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction CancerTreatment
NCT01364493A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric CancerTreatment
NCT01130337A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric CancerTreatment